Test Price
2,800 AED✅ Home Collection Available
B4GALNT1 Gene (SPG26) Genetic Test in UAE – NGS Sequencing | 2,800 AED
Executive Summary – Accuracy, Privacy & UAE-Compliant Genetic Testing
- Diagnostic Precision: 99.9% analytical sensitivity for pathogenic B4GALNT1 variants via ISO‑certified NGS.
- Premium Home Collection: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM) across Dubai, Abu Dhabi, and all Emirates.
- Clinical Interpretation: Post‑test telephonic guidance with a DHA‑licensed Medical Genetics consultant, ensuring safe result integration.
- Insurance Support: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
Comprehensive Gene Test for Hereditary Spastic Paraplegia Type 26 (SPG26)
This next‑generation sequencing (NGS) assay targets the entire B4GALNT1 gene to diagnose autosomal recessive SPG26, a progressive upper motor neuron disorder. The test is indicated for patients with clinical spastic paraplegia, family history, or carrier testing, and delivers definitive molecular confirmation in as fast as 3–4 weeks.
| Feature | Our B4GALNT1 NGS Test | Standard Single‑Gene Sanger Sequencing |
|---|---|---|
| Mutation Coverage | Full gene (coding exons ± flanking intronic regions), detects SNVs, small indels, and copy‑number variations if designed | Limited to targeted amplicons; may miss deep intronic or regulatory variants |
| Sensitivity | >99.9% for pathogenic variants within covered regions | ~99% for specific point mutations, low detection of large rearrangements |
| Turnaround Time | 3–4 weeks | 4–6 weeks (often requires MLPA add‑on for deletions) |
Physician Insight & Safety Protocols
“A positive B4GALNT1 result must always be correlated with the patient’s clinical picture and family history. This test is a powerful tool for confirming SPG26, but it is not a substitute for a complete neurological evaluation and genetic counselling.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Advisory Notice
Important Safety Information
This genetic test result should not be used as the sole basis for altering any prescribed treatment or medication regimen. Always consult with your treating physician before making changes to your care plan. The test provides diagnostic support and does not replace clinical judgment.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Inability to give informed consent.
- Uncontrolled bleeding diathesis precluding safe venipuncture.
- Known allergy to antiseptic agents used in phlebotomy.
Urgent Red Flags
If you experience acute neurological worsening (sudden vision loss, severe headache, breathing difficulty, or paralysis) before the blood collection, proceed to the nearest emergency department immediately. Inform the home collection team only after stabilization.
Patient FAQ & Clinical Guidance
1. What does the B4GALNT1 genetic test diagnose?
This advanced NGS test accurately identifies B4GALNT1 gene mutations to definitively diagnose hereditary spastic paraplegia type 26 (SPG26). It confirms the genetic cause behind progressive leg stiffness, gait difficulties, and possible bladder involvement, guiding targeted management and family risk assessment.
2. How is the B4GALNT1 genetic test performed in the UAE?
A simple blood sample is collected from your home by our certified nursing team using temperature-controlled cold-chain logistics. The sample is then analyzed using advanced NGS technology to identify mutations causing SPG26. Results are typically available within 3–4 weeks, followed by a comprehensive tele-genetic counselling session.
3. Is genetic counselling required before testing?
Yes, pre‑test genetic counselling is mandatory to draw a pedigree and discuss implications before the B4GALNT1 NGS. Our tele‑counselling service meets UAE PDPL and Federal Law No. 2 of 2019 requirements, ensuring informed consent, family history mapping, and clear expectation setting for results that may affect at‑risk relatives.
UAE Regulatory & Data Privacy Adherence
Compliance & Data Protection Framework
This genetic test is performed under the regulatory oversight of the Dubai Health Authority (DHA) and complies with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring your genetic data is securely processed and stored.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing electronic health information exchange.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – safeguarding patient consent and clinical safety.
Our laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | B4GALNT1 Gene (SPG26) Full Gene Sequencing – NGS |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (3–5 mL in EDTA tube) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection |
| Methodology Used | Next‑Generation Sequencing (NGS) – Illumina platform, whole gene coding exons and flanking intronic regions |
| ICD-10-CM Code | G11.4 |
| LOINC Code | 48018-6 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians